Acalabrutinib
- Generic Name
- Acalabrutinib
- Brand Names
- Calquence
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23N7O2
- CAS Number
- 1420477-60-6
- Unique Ingredient Identifier
- I42748ELQW
- Background
To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others.
...
- Indication
Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy. It has also been recently approved for chronic lymphocytic leukemia and small lymphocytic lymphoma.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma
- Associated Therapies
- -
A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 30
- Registration Number
- NCT05140096
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Shayna Sarosiek, MD
- Target Recruit Count
- 33
- Registration Number
- NCT05065554
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-09-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 607
- Registration Number
- NCT05057494
- Locations
- 🇪🇸
Research Site, Palma de Mallorca, Spain
Preventing Anaphylaxis With Acalabrutinib
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 10
- Registration Number
- NCT05038904
- Locations
- 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Public Health Emergency: SOLIDARITY TRIAL Philippines
- Conditions
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- University of the Philippines
- Target Recruit Count
- 1314
- Registration Number
- NCT05024006
- Locations
- 🇵🇭
Chinese General Hospital, Manila, Metro Manila, Philippines
🇵🇭UP - Philippine General Hospital, Manila, Metro Manila, Philippines
🇵🇭San Juan de Dios Educational Foundation Inc - Hospital, Pasay, Metro Manila, Philippines
Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- University College, London
- Target Recruit Count
- 26
- Registration Number
- NCT05004064
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04978584
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
- Conditions
- Interventions
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT04941716
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Acalabrutinib in CNSL
- Conditions
- Interventions
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 49
- Registration Number
- NCT04906902
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 12
- Registration Number
- NCT04905043
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.